Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALT
- Price
- 4.41
- Stock movement up
- +0.25 (6.01%)
- Company name
- Altimmune Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 313.66M
- Ent value
- 296.67M
- Price/Sales
- 6031.91
- Price/Book
- 2.35
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -34.69%
- 1 year return
- -44.94%
- 3 year return
- -9.55%
- 5 year return
- 5.65%
- 10 year return
- -37.63%
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ALT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6031.91 |
| Price to Book | 2.35 |
| EV to Sales | 5705.24 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 71.12M |
| EPS (TTM) | -1.46 |
| FCF per share (TTM) | -1.10 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 52.00K |
| Gross profit (TTM) | -2.01M |
| Operating income (TTM) | -99.51M |
| Net income (TTM) | -103.52M |
| EPS (TTM) | -1.46 |
| EPS (1y forward) | -1.13 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -3857.69% |
| Operating margin (TTM) | -191365.38% |
| Profit margin (TTM) | -199076.92% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 31.47M |
| Net receivables | 428.00K |
| Total current assets | 145.76M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 147.86M |
| Accounts payable | 1.13M |
| Short/Current long term debt | 1.77M |
| Total current liabilities | 8.64M |
| Total liabilities | 14.49M |
| Shareholder's equity | 133.38M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -78.12M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -78.12M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -77.61% |
| Return on Assets | -70.01% |
| Return on Invested Capital | -77.43% |
| Cash Return on Invested Capital | -58.43% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.17 |
| Daily high | 4.41 |
| Daily low | 4.12 |
| Daily Volume | 1.42M |
| All-time high | 2724.00 |
| 1y analyst estimate | 22.86 |
| Beta | 0.07 |
| EPS (TTM) | -1.46 |
| Dividend per share | - |
| Ex-div date | 6 Feb 2017 |
| Next earnings date | 7 May 2025 |
Downside potential
Loading...
Downside potential data
| ALT | S&P500 | |
| Current price drop from All-time high | -99.84% | -12.89% |
| Highest price drop | -99.94% | -56.47% |
| Date of highest drop | 19 Nov 2019 | 9 Mar 2009 |
| Avg drop from high | -79.90% | -11.07% |
| Avg time to new high | 244 days | 12 days |
| Max time to new high | 4765 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
313.66M
Marketcap category
Small-cap
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Employees
59
Website
Investor relations
SEC filings
CEO
Vipin K. Garg
Country
USA
City
Gaithersburg
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page